Shawn Marshall Rose - 06 Jan 2026 Form 4 Insider Report for Nkarta, Inc. (NKTX)

Role
Chief Medical Officer, Head of Research & Development
Signature
/s/ Bridgette Housley, as Attorney-in-Fact
Issuer symbol
NKTX
Transactions as of
06 Jan 2026
Net transactions value
$0
Form type
4
Filing time
08 Jan 2026, 17:50:36 UTC
Previous filing
25 Jun 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Rose Shawn Marshall Chief Medical Officer, Head of Research & Development C/O NKARTA, INC., 1150 VETERANS BLVD, SOUTH SAN FRANCISCO /s/ Bridgette Housley, as Attorney-in-Fact 08 Jan 2026 0002073530

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction NKTX Common Stock Award $0 +70,000 $0.000000 70,000 06 Jan 2026 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction NKTX Stock Option (right to buy) Award $0 +139,000 $0.000000 139,000 06 Jan 2026 Common Stock 139,000 $1.93 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents Restricted Stock Units ("RSUs") which vest in four equal annual installments beginning on January 14, 2027. Each RSU represents a contingent right to receive one share of Common Stock of the Issuer.
F2 This option is scheduled to vest and become exercisable in 48 equal monthly installments occurring on the completion of each successive month of the Reporting Person's service to the Issuer following January 14, 2026.

Remarks:

Chief Medical Officer, Head of Research & Development